Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study ...

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) Thursday for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The combination treatment reduced the need for ...

* NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) SAYS TRIAL IS NOW ENROLLING HOSPITALIZED ADULTS WITH COVID-19 IN THE UNITED STATES * NIAID SAYS TRIAL IS EXPECTED TO OPEN AT ...

Nov 19 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's (LLY.N), opens new tab arthritis drug, baricitinib, in combination with Gilead ...

A 25% lower all-cause mortality is associated with timely initiation of remdesivir in immunocompromised patients hospitalized for COVID-19. Among patients with immunocompromising conditions who were ...

The World Health Organization has updated its ongoing guidance on Covid-19 medications to advise against using the antiviral drug remdesivir to treat hospitalized patients, no matter how severe their ...